Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmacyclics, a developer of small-molecule drugs for the treatment of cancer and immune mediated diseases, has reported total revenues of $1.39m for the fourth quarter ended 30 June 2011, compared to $2.49m for the same period in 2010.
Subscribe to our email newsletter
Pharmacyclics’ net loss was $10.96m for the fourth quarter ended 30 June 2011, compared to $6.84, for the same period in 2010.
The company’s loss from operations were $11m, compared to $6.86m for the same period in 2010.
For the full year ended 30 June 2011, the company reported a net revenues of $8.23m, compared to $9.31m for the same period in 2010.
The company has reported net loss of $35.2m for the full year ended 30 June 2011, as compared to $15.61m for the same period in the prior year.
Pharmacyclics’ loss from operations were $35.37m for the full year ended 30 June 2011, compared to $15.61m for the same period last year.
Pharmacyclics CEO and chairman of the board Bob Duggan said they plan to initiate their first Phase III trial for 32765 in this fiscal year ending 30 June 2012.